- Home
- » Tags
- » Janssen Pharmaceuticals
Top View
- RISPERDAL-Pi.Pdf
- Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX® Marketing and Promotional Activities
- The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls
- COMPLAINT JURY TRIAL DEMANDED Plaintiffs, V. P
- The Supreme Court of South Carolina
- Denice Torres Chief Strategy & Business Transformation Officer Johnson & Johnson Medical Devices
- Buncombe Complaint Final (00518783).DOCX
- Risperdal), Diabetes (Invokana), Psoriasis (Stelara), Migraines (Topamax), Heart Disease (Xarelto) and Attention Deficit Disorder (Concerta)
- Ketoconazole) Tablets
- Mcneil-JANSSEN PHARMACEUTICALS, INC
- 1:20-Cv-03471 Document #: 370 Filed: 02/03/21 Page 1 of 27 Pageid #:27504
- Health Care Law Monthly
- Kidney Week Disclosures
- 2020 Annual Report • • Failure to Meet Compliance Obligations in the Mcneil-PPC, Inc
- SPRAVATO® (Esketamine) Nasal Spray, CIII
- Johnson & Johnson
- Reference ID: 3027004 Interacting Drug Interaction • Pediatrics: Musculoskeletal Disorders (Arthralgia, Arthritis, Warfarin Effect May Be Enhanced
- 2019 Janssen U.S. Transparency Report Notes on This Report
- EXHIBIT 21 SUBSIDIARIES Johnson & Johnson, a New Jersey
- Faculty Disclosure Index DDW Sponsoring Society CME Statements
- 2012 ANNUAL REPORT This Year We’Ve Created a Fully Interactive, Digital, Online Annual Report Where You Can Find Our Stories of Caring
- New Antihistamines – Perspectives in the Treatment of Some Allergic and Inflammatory Disorders
- Defendants, Janssen Pharmaceuticals, Inc. and Johnson & Johnson, And
- ASN Kidney Week 2019 Disclosures 1
- We Received This After Hours on Friday So the Deadline Is Friday, May 31. From: Office of the Vermont Attorney General <Ago.H